

Index

- 1-fluoro-2,4-dinitrobenzene (FDNB), 189
 5-hydroxytryptamine (5-HT), 113
- A-band, 123–124, 141
 absolute refractory period, 20, 211
 accommodation, 85
 acetylcholine (ACh), 90, 92, 94, 99–101, 106
 acetylcholine receptors (AChRs), 99
 muscarinic, 111, 113–114
 nicotinic, 101–103, 111, 113–114
 acetylcholinesterase, 91
 actin, 124–125, 129
 myosin, ATP interactions, 130–131
 smooth muscle, 252, 265
 tropomyosin and troponin, 131
 actinin, 132, 252
 action potential. *See also* excitation
 activation abnormalities, 235–238
 cardiac, 202–203, 226
 cardiac vs skeletal muscle, 216–218
 computed and experimental, 53
 conduction, 78–79
 conduction abnormalities, 236–238
 electrical recording, 10–12
 extracellular recording, 14–17
 generation, 88, 228–230
 impedance changes, 41
 intracellular recording, 13–14
 propagation, 228–230
 repolarisation abnormalities, 238
 surface/transverse tubules, 143–145
 action potential duration, 229, 231–232, 241
 alternans, 232
 action potential recovery, 230–231, 240, 242
 action potential wavelength, 228
 activation, molecular basis, 131–132
 active force, 134
 active region of excitation, 79
 active spots, 141
 active transport, ions, 32–37
 actomyosin, 130–131
 adenylyl cyclase, 113, 115, 218, 221
 adipose tissue lipid, 191
 ADP, 189
 adrenaline (epinephrine), 218, 253
- aequorin, 157–158
 aerobic respiration, 191
 afferent sensory nerves, 1
 African clawed toad *Xenopus*, 57, 103
 after-depolarisations, 234
 after-loads, 183–184
 after-potential, 3, 87
 Ag/AgCl electrode, 12
 alanine, 56
 all-or-nothing behaviour, 14, 18
 amino acids, 55–57, 59, 102
 ammonium chloride, 31–32
 AMPA receptor, 117–118
 amplifiers, 11
 anaerobic respiration, 191
 animal models
 arrhythmogenesis, 226
 hypokalaemic murine, 242–243
 anode break excitation, 86
 anti-arrhythmic drugs, classification, 251
 anti-cholinesterases, 94
 antipyrilazo III, 157–158, 160
 arginine, 56, 59, 67
 arginine phosphate, 34
 arrhythmic substrate, 228–233
 arrhythmic triggers, 233–234
 arrhythmogenesis. *See* cardiac arrhythmogenesis
 arsenazo III, 157–158
 asparagine, 56
 aspartate, 59
 aspartic acid, 56
 astrocytes, 119
 asymmetry currents, 62
 ATP, 113, 189–190
 actin, myosin interactions, 130–131
 Na⁺ extrusion, 34
 production, 191
 ATPase activity, 128
 atrial arrhythmia, 225–226, 235, 250
 atrial fibrillation, 225–226
 atrial myocytes, 212, 214
 atrioventricular node (AVN), 200–201
 block, 226
 pacemaker, 207
 auto-antibodies, 104
 autonomic nervous system, 1
 autoradiography, 102
- axons, 2, 88
 excitation along, 76–78
 myelinated, 4–8
 regeneration, 8–9
 unmyelinated, 2–3
 voltage changes along, 74–75
 axoplasm, 3, 5, 25
- Balanus nubilis*, 158
 basic cycle length, 229, 232
 beta-adrenergic receptors, 114, 263
 botulinum toxin, 104
 Brugada syndrome, 231, 236
 bundle of His, 200–201
 bungarotoxin, 101–102, 104
- cable systems, 73–74
 cable theory, 148
 caffeine, 170, 173, 177–178
 calcium channels
 cardiac muscle, 209, 214
 gain of function, 242
 permeation, 69
 voltage-gated, 58
 calcium ions (Ca²⁺)
 arrhythmias, 247
 contractile activation, 265–267
 excitation, 86
 excitation–contraction coupling, 155–156, 158–160
 homeostasis, 221–223, 244–247
 measurement of, 156–158
 MEPP production and, 95
 sarcolemmal reticular, 162–164, 167–169, 175–176
 voltage-dependent release of, 158–160
 caldesmon, 266
 calmodulin, 117–118, 163, 198, 266
 calomel electrode, 10
 calsequestrin, 162, 175–176, 245
 capacitance, 41, 47, 79, 147
 capacitative currents, 63–64
 cardiac action potential, 202–203, 216–218, 226
 cardiac arrhythmias, 79, 225, 270
 atrial. *See* atrial arrhythmia
 ventricular. *See* ventricular arrhythmia
 cardiac arrhythmogenesis, 225–228

- arrhythmic substrate, 228–233
 arrhythmic triggers, 233–234
 calcium mediated, 247
 pro-arrhythmia, 244, 248–249
 therapeutic strategy, 249–251
- cardiac cells, 200
 cardiac electrophysiology, 203–205
 cardiac muscle, 121
 calcium ion release, 214
 excitation–contraction coupling, 212–214, 221–223
 ionic currents, 206–207, 211
 nervous control of, 218–221
 prolonged refractory period, 211
 recovery from excitation, 215–216
 titin, 133–134
 vs skeletal muscle, action potentials, 216–218
- Casq2, 245, 247
 catecholaminergic polymorphic VT, 234, 245–247
- cathode-ray oscilloscope, 11
 cDNA sequencing, 55, 57
 cell body, 2, 106
 cell membrane
 charge movements in, 62–65
 depolarisation, 44
 excitation in smooth muscle, 259–260
 nerve, 3, 47–49
 potential. *See* membrane potential
 skeletal. *See* skeletal muscle membrane
 structure of, 22–25
- cell volume, 32
 changes, 193, 196
- cellular ionic regulatory mechanisms, 197
- central nervous system, 1
 channel proteins, 60–61
 charge movements, 62–65
 chloride ions (Cl⁻), 26–30, 136
 cholesterol, 22
 cisternal membrane, 161
 conductances, background, 135–136
- conduction velocity, 16, 54, 78–79, 84–85, 148
 congenital LQTS, 243
 connexins, 116
 connexons, 116
 constant field equation, 27, 48
- contraction
 activation in smooth muscle, 265–267
 excitation–contraction. *See* excitation–contraction coupling
 molecular basis of, 127
 muscle. *See* muscle contraction
 sarcomeres, 132–134
- cortical spreading depression, 120
- creatine phosphate, 189–190
 creatine phosphotransferase, 189
 creatinine phosphokinase, 122
 crossbridge cycling, 266, 268
 crossbridge filaments, 123, 125
 crossbridges, 126
 cryo-electron microscopy (cryo-EM), 58, 69, 102, 163
- curare, 91, 93–94, 104
 cyanide ions (CN⁻), 34
 cyclic AMP, 113, 115, 218
 cysteine, 56
- dantrolene, 175, 177, 179
 daunorubicin, 168, 170–171
 delayed after-depolarisations, 234
 dendrites, 2, 106
 dephosphorylation, 267
 depolarisation, 17, 44, 85
 delayed after, 234
 early after, 234
 phase 0 208
 slow wave, 259
- depression, 97
 cortical spreading, 120
- diastolic interval, 228, 232
- digitalis, 216
- dihydropyridine receptors (DHPRs), 164, 167
 cardiac muscle, 212
 ryanodine receptor coupling, 169–174
- dinitrophenol, 34, 36
- diphasic recording, 15
- direct inhibitory pathway, 109
- DNA
 cDNA sequencing, 55, 57
 recombinant, 55, 102
- Donnan equilibrium system, 28–30
 direct tests of, 31–32
- dopamine, 113
- double Donnan system, 32
- duration, shock, 20
- dystrophin, 122
- early after-depolarisations, 234
 effective refractory period, 78, 227
 efferent motor nerves, 1
 efficiency, muscle, 187
 electrical circuit, 47–49
 electrical impedance, 41
 electrical recording, 10–12
 excitation, 17–21
 extracellular, 14–17
 intracellular, 13–14
- electrical resistance, 3, 7
 electrical work, 26
- electrocardiogram (ECG), 203–205
 cardiac arrhythmias, 225
 interpretation of, 205–206
- electrodes, reversible, 10
- electromotive force, 47
- electron microscopy, 23, 89, 102, 116, 123, 125
 cryo-EM, 58, 69, 102, 163
- electroneutrality, 30
- Electrophorus*, 14, 55
- electrophysiology
 cardiac, 203–205
 surface/transverse tubules, 145–149
 temporal heterogeneities, 231–233, 241, 243
- electrotonic properties, 75–76
- electrotonic synapses, 116
- endomysium, 122
- endoneurium, 8
- end-plate function, 91
- end-plate potential (EPP), 91–96
 EPSPs and, 108–109
 ionic current flows, 97–99
- epimysium, 122
- epinephrine (adrenaline), 218, 253
- epineurium, 8
- equilibrium potential, 27–28, 47
- equivalent electrical circuit, 47–49
- eserine, 104
- excitation, 17–21. *See also* action potential
 active region of, 79
 anode break, 86
 cardiac muscle recovery from, 215–216
 charge movements and, 62–65
 impedance changes during, 41
 membrane in smooth muscle, 259–260
 surface/transverse tubules, 147–149

- excitation (cont.)
 synaptic, in motor neurons, 106
 threshold for, 85–87
 unmyelinated nerve, 76–78
- excitation–contraction coupling,
 154–179
 calcium ions and, 155–156, 158–160
 cardiac, 212–214, 221–223
 membrane potential and, 154–155
 smooth muscle, 260–262, 269–270
 tubular voltage detection, 164–167
- excitatory postsynaptic currents
 (EPSCs), 97–99
- excitatory postsynaptic potentials
 (EPSPs), 107–109
 fast and slow, 112
 IPSPs and, 110–111
 late slow, 113
- exercise, 199
 energy balances during, 202–203
 osmosis and, 202–203
 transverse tubule changes during,
 152–153
- extracellular recording
 cardiac electrophysiology, 203–205
 nervous impulse, 14–17
- extrasystolic triggering, 245
- eye, smooth muscle cells, 253
- facilitation, 97
- fast-twitch muscles, 121, 181
- fatigue, muscle, 192
- feedback action, excitation–
 contraction coupling, 176–179,
 221–223
- feedforward action, 218–221
- filaments, 123
 isometric tension, 125–127
 length of, 123
 myosin, 128
 sliding-filament theory, 124
 thin filament model, 131
- flame photometry, 25
- flecainide, 238–239
- fluid mosaic model, 23
- force–velocity curve, 184–186
- Frank–Starling Law, 218
- fusion frequency, 182
- G-protein, 113–115
- G-protein-linked receptors, 114–116
- gamma-aminobutyric acid (GABA),
 110, 113
- ganglia, 1
- gap junctions, 116, 252
- Gasser's reconstructions, 16
- gastrointestinal muscles, 253–254
- gating currents, 62, 65–66
- glass microelectrodes, 10
- glial buffering, 118–120
- glucose, 188, 191
- glutamate, 59, 119
- glutamate receptors, 109, 113,
 117–118
- glutamic acid, 56
- glutamine, 56, 59
- glycerol, 146
- glycine, 56, 110
- glycine receptors, 110
- glycogen, 188, 191
- Goldman constant field equation, 27
- Golgi tendon organs, 17
- green fluorescent protein, 158
- grey matter, 7
- group Ia fibres, 107, 109–110, 112
- guanosine triphosphate (GTP), 113
- halogenated volatile anaesthetics, 174
- heart. *See* cardiac muscle
- heartbeat, 201–202
- heat production, 187
- heavy meromyosin, 128
- hexamers, 116
- high-energy phosphate, 34, 189, 191
- Hill equation, 185
- histidine, 56
- homeostasis
 calcium ions, 221–223, 244–247
 resting cellular ions, 38–39
- hydrazine, 68–69
- hydrogen ion buffering, 203–205
- hydropathy index, 56, 58
- hydrophilic heads, 22–23
- hydrophobic constriction site, 67
- hydrophobic tails, 22–23
- hydroxylamine, 68–69
- hyperpolarisation, 87
- hyperthermia, malignant, 174
- hypokalaemic murine models,
 242–243
- I band, 124, 141
- in vitro* motility assays, 131
- inactivation, 44
- inactivation gate, 67
- independence principle, 69–72
- inhibitory postsynaptic potentials
 (IPSPs), 110–111
- inositol trisphosphate (IP₃), 113, 115,
 256
- intercalated discs, 200, 217
- interference microscopy, 123–124
- interneurons, 1
- interstitial cells of Cajal, 254–255
 abnormal, 270
 electrical coupling, 258–259
 pacing properties, 255–258
- interstitial space, 118–120
- intracellular microelectrode, 94, 106,
 149
- intracellular recording, membrane
 potential, 13–14
- inulin, 25
- iodoacetate, 189
- ion balances, during exercise,
 195–197
- ion channels. *See also individual ion
 channels*
 ligand-gated, 103
 neurotransmitter actions on, 114
 single, 100
 store-operated and
 mechanosensitive, 265
 voltage-gated. *See* voltage-gated ion
 channels
- ionic current, 48
 cardiac muscle, 206–207, 211
 end-plate potentials, 97–99
 mathematical formulation of
 properties, 52–54
 separation of components, 49–52
 skeletal muscle, 137–140
- ionic selectivity, 68–69
- ionophoresis, 92, 104
- ionotropic receptors, 113
- ions
 active transport of, 32–37
 distribution in nerve and muscle, 25
 occupancy, 69–72
 resting cellular ion homeostasis,
 38–39
- ischaemia, 206, 248, 270
- isoleucine, 56, 59
- isometric contraction, 180
- isometric tension, 125–127, 185–186
- isometric twitch, 181–183
- isotonic contraction, 180, 183–185
- isotonic twitch, 186, 189
- Japanese puffer-fish poison, 51, 56
- Jervell and Lange–Nielsen syndrome,
 239

- Kir channels, 135, 137
 knee-jerk reflex, 108
 knock-in models, 226
 knock-out models, 227
- lactate, 192–194
 Langendorff perfusion, 240, 242, 244
 latch bridges, 268
 late slow EPSP, 113
 latrotoxin, 104
 law of conservation of energy, 185
 length–tension curve, 182, 185
 leucine, 56, 103
 lidocaine, 166
 ligand-gated channels, 103
 light meromyosin, 128
 lipids, 22
 bilayers, 22–23
 phospholipids, 22–23
 local circuit currents, 77
 local circuit theory, 18
 long QT syndrome (LQTS), 238–239
 congenital, 243
 hypokalaemia, 242–243
 LQTS3, 239–242
 LQTS8, 242
 long-term potentiation, 117
 longitudinal current, 80, 82
 lysine, 56, 59
- magnesium ions (Mg^{2+}), 86
 malignant hyperthermia, 174
 mechanical summation, 182
 mechanosensitive channels, 265
 membrane potential
 after-potential, 3, 87
 excitation–contraction coupling
 and, 154–155
 intracellular recording, 13–14
 membrane proteins, 23
 meromyosin, 128
 mesaxon, 3
 messenger RNA, 55, 57, 103
 metabolic disorders, 206
 metabotropic receptors, 113
 metallochromic dyes, 157–158
 methionine, 56
 methylamine, 68–69
 miniature end-plate potential (MEPP),
 92, 94–96
 mitochondria, 7, 90, 222
 molecular cloning, 55–56, 114
 monophasic recording, 15–16
 monosynaptic reflex, 108–109
- motor nerve cells, 1–2
 motor neurons, 88, 121
 inhibition in, 109–110
 IPSP/EPSP interactions, 110
 synaptic excitation in, 106
 motor unit, 88–89
 murine hypokalaemic models,
 242–243
 muscarinic receptors, 111, 113–114
 muscle contraction, 180–199
 energetics of, 185
 energy source for, 188–190
 heat production, 187
 mechanism, 121–134
 work and power output, 186
 muscle dystrophy, 122, 153
 muscle fibres
 innervation, 88
 presynaptic transmitter release,
 89–91
 subtypes, 121
 muscles
 Donnan equilibrium system in,
 28–30
 efficiency, 187
 fatigue, 192
 ion distributions in, 25
 myasthenia gravis, 104
 myelin sheath, 4, 7, 80
 myelinated axons, 4–8
 myelinated nerves
 conduction velocity, 84
 saltatory conduction, 79–84
 myoblast, 121
 myofibrils, 122–124
 myoglobin, 122
 myosin, 124–125, 127–129, 265
 actin, ATP interactions, 130–131
 myosin light chain, 266–268
 myosin light chain kinase, 266–267
 myotonia congenita, 153
 myotonic dystrophy, 153
- Nav1.5 function, 235
 NCX exchanger, 215
 nebulin, 132
 needle biopsy, 197
 negative after-potential, 87
 Nernst equilibrium potential, 47
 Nernst potential, 27, 98
 nerve cells, 1
 nerve fibres. *See* axons
 nerve membrane, 3
 equivalent electrical circuit, 47–49
- nerves, ion distributions in, 25
 nervous impulse, extracellular
 recording, 14–17
 nervous system, 1
 neurilemma, 8
 neuromuscular junction, 89
 pharmacological properties,
 103–105
 neuromuscular transmission, 88
 neurons, 2
 neuropeptides, 113
 neurotransmitter receptors, 113
 neurotransmitter-gated channels, 103
 neurotransmitters, 106
 actions on ion channels, 114
 presynaptic release, 89–91
 quantal theory of release, 95
 nicotine, 104
 nicotinic receptors, 101–103, 111,
 113–114
 nifedipine, 167, 173, 209, 243
 Nissl bodies, 8
 nitrogen, 189
 NMDA receptor, 113, 117
 N-methyl-D-aspartate (NMDA), 113
 nodes of Ranvier, 4, 6
 noradrenaline (norepinephrine), 113,
 218, 264
- olfactory nerve, 3–4
 oligodendroglial cells, 4
 osmosis, exercise and, 203–205
 osmotic shock, 146, 192
 ouabain, 35, 37
 oxygen, 122, 191
 reactive species, 163, 222, 248
- P-wave, 205–206
 p21 activated kinase-1 (Pak1), 247
 pacemakers
 activity, 201, 203, 207
 implants, 225
 interstitial cells of Cajal, 254–258
 potential, 203
 papain, 128
 parasympathetic nervous system, 1,
 220
 passive force, 133
 patch clamp studies, 99–101
 perchlorate, 170, 172–173
 perimysium, 121
 perineurium, 8
 peripheral nerves, 88
 peripheral nervous system, 1

- permeability coefficients, 28
 permeation, voltage-gated channels, 69–72
 pharmacomechanical coupling, 262–263
 Phase 0 depolarisation, 208
 Phase 1 repolarisation, 209
 Phase 2 plateau, 209
 Phase 3 repolarisation, 210
 Phase 4 electrical diastole, 210
 phase-contrast microscopy, 123–124
 phenylalanine, 56
 phenylglyoxal, 167
 phosphate, high-energy, 34, 189, 191
 phosphatidyl inositol, 115
 phospholipids, 22–23
 phosphorylation, 266–268
 photomultiplier tube, 158
 physostigmine, 104
 Poisson distribution, 96
 polypeptides, 57–58, 127
 pore module, 58
 positive after-potential, 87
 positive feedback, 44
 positive phase, 13, 87
 postcathodal depression, 86
 postsynaptic membrane, 89
 postsynaptic recordings, 94–97
 postsynaptic response, 91–94
 post-tetanic hyperpolarisation, 87
 potassium channels, 37
 cardiac muscle, 209–210
 loss of function, 242–244
 permeation, 69, 71
 potassium ions (K⁺)
 buffering, 119
 Donnan equilibrium, 28–30
 resting potential and, 26–27
 sodium pump and, 35
 power output, 186
 PR interval, 206
 preload, 183
 presynaptic events, 94–97
 presynaptic inhibition, 111
 presynaptic region, 89
 presynaptic transmitter release, 89–91
 pro-arrhythmia, 244, 248–249
 proline, 56
 propagation
 action potential, 228–230
 nerve impulse, 18
 slow wave, 258–259, 270
 propranolol, 240
 protein ions, 28–30
 protein kinase A, 218
 proteins, 55–57
 channel proteins, 60–61
 membrane, 23
 protons (H⁺), 28, 32
 Purkinje fibres, 201–202

 QRS complex, 205–206
 QT interval, 206
 quantal content, 96
 quantal presynaptic events, 94–97
 quinidine, 239

 reactive oxygen species, 163, 222, 248
 recombinant DNA, 55, 102
 refractoriness, 78
 refractory period
 absolute, 20, 211
 effective, 78, 227
 prolonged, 211
 relative, 21
 regeneration, axons, 8–9
 relative refractory period, 21
 repolarisation
 action potential abnormalities, 238
 phase 1 209
 phase 3 210
 sarcoplasmic reticular calcium ions and, 175–176
 transmural, 230
 resistance, 3, 7, 41, 47, 73, 148
 respiration, 188, 191
 resting cellular ion homeostasis, 38–39
 resting potential
 electrical recording, 10–12
 genesis of, 26–27
 intracellular recording, 13–14
 skeletal muscles, 136
 reversal potential, 98
 reversible electrodes, 10
 rheobase, 20
 rhodopsin, 17, 114
 rhythm disorders, 206
 right ventricular outflow tract, 236–237
 RNA, messenger, 55, 57, 103
 Romano–Ward Syndrome, 239
 ruthenium red, 168
 ryanodine, 162, 170–172
 ryanodine receptor (RyR), 162–164
 cardiac muscle, 212
 dihydropyridine receptor coupling, 169–174
 malignant hyperthermia and, 174
 sarcoplasmic reticular calcium ions, 167–169
 sodium ions, 176–179

 S4 segment, 67, 103, 167
 saltatory conduction, 7, 79–83
 sarcolemma, 122
 sarcomere, 123
 contracting, 132–134
 length of, 125–127
 sarcopaenia, age-related, 198
 sarcoplasmic reticular Ca²⁺-ATPase (SERCA), 175, 209
 sarcoplasmic reticulum (SR), 122, 141
 calcium ions, 162–164, 167–169, 175–176
 cardiac, 200
 smooth muscle, 252
 triad complexes, 160–162
 Schwann cells, 3, 5
 myelinated axons, 4, 7
 screw-helical mechanism, 68
 second messengers, 113
 sensory nerve cells, 1–2
 sensory nerves, 88
Sepia axon, 42, 44
 serial synapses, 111
 serine, 56
Shaker gene, 56, 68
 silver/silver chloride electrode, 10
 single ion channels, 100
 sino-atrial node (SAN), 200
 disorders, 225
 pacemaker, 207
 pacemaker cells, 201, 203
 skeletal muscle, 121
 activation, 135–153
 activation, molecular basis of, 131–132
 anatomy, 121–122
 atrophy, 198
 contraction. *See* muscle contraction
 excitation–contraction coupling. *See* excitation–contraction coupling
 innervation, 88
 trophic changes in, 197–198
 vs cardiac muscle, action potentials, 216–218
 skeletal muscle membrane. *See also* surface tubular membrane, *See also* transverse tubular membrane

- background conductances, 135–136
 ionic currents, 137–140
 sliding-filament theory, 124
 slow synaptic potentials, 111–114
 slow-twitch muscles, 121, 181
 slow-wave propagation, 258–259, 270
 smooth muscle, 121, 252, *See also*
 interstitial cells of Cajal
 contractile activation, 265–267
 electrical coupling, 258–259
 excitation–contraction coupling, 260–262, 269–270
 functional features, 253
 ion channels, 265
 mechanical properties, 268
 membrane excitation, 259–260
 pharmacomechanical coupling, 262–263
 smooth muscle cells, 252–253
 sodium channels, 32–37, 208
 gain of function, 239–242
 gating mechanism, 66–68
 impaired function, 235–238
 ryanodine receptor and, 176–179
 voltage-gated, 57, 59–60
 sodium hypothesis, 41–44
 predictions of, 43–46
 sodium pump, 33–37
 soleus, 121, 150, 181
 soma, 106, 110
 space constant, 76
 spatial buffering, 119
 spatial heterogeneities, 228–231
 spatial summation, 108
 spike. *See* excitation, *See* action potential
 squid giant axon, 3, 5
 ST segment, 205–206
 steady-state space constant, 76
 stilbene chromophores, 157–158
 store-operated channels, 265
 strength–duration curve, 20
 striated muscle, 121–123
 stroke, 226
 supernormal period, 21
 surface-membrane excitation, 148
 surface monophasic action potential, 227
 suxamethonium, 174
 swinging lever model, 130
 sympathetic nervous system, 1, 218
 synapses, 2, 88
 electrotonic, 116
 serial, 111
 synaptic cleft, 89, 91, 107
 synaptic delay, 95
 synaptic excitation, 106
 synaptic transmission, 106
 synaptic vesicles, 89–90, 96, 107
 syncytium, 200–202, 259
 T-wave, 205
 tachycardias. *See* ventricular tachycardias
 temporal electrophysiological heterogeneities, 231–233, 241, 243
 temporal summation, 108
 tension, 127, 182, 185–186
 tetanus, 182
 tetracaine, 168, 172–173
 tetrads, 164, 170
 tetrodotoxin (TTX), 51, 56, 94
 thin filament model, 131
 threonine, 56
 threshold stimulus, 18–19
 Timothy syndrome, 242
 titin, 132–134
 tonic muscle fibres, 88
Torpedo (electric ray), 102–103
 torsades de pointes, 225–226
 transfer impedance, 149
 transmural repolarisation, 230
 transverse (T-) tubular membrane, 141–143
 action potential, 143–145
 altered properties of, 153
 changes during exercise, 152–153
 electrophysiology, 145–149
 physiological modulation, 150–151
 triad complexes, 160–162
 transverse (T-) tubules, 122
 transverse current, 82
 triads, 160–162
 tropomyosin, 124, 130–132, 265
 troponin, 124, 130–131
 trypsin, 128
 tryptophan, 56
 tubocurarine, 104
 tubular membrane, 141–143
 action potential, 143–145
 electrophysiology, 145–149
 physiological modulation, 150–151
 tubular voltage detection, 164–167
 twitch muscle fibres, 88
 fast and slow, 121, 181
 isometric, 181–183
 tyrosine, 56
 tyrosine kinase, 104
 unmyelinated axons, 2–3
 unmyelinated nerves
 conduction velocity, 84
 excitation along, 76–78
 voltages changes along, 75
 vagal nerve stimulation, 90
 valine, 56
 velocity
 action potential conduction, 78–79
 conduction, 84–85
 force–velocity curve, 184–186
 ventricular arrhythmias, 225–226, 236–239, 250
 ventricular myocytes, 214
 ventricular tachycardias, 226, 234, 245–247
 verapamil, 209
 vesicular sarcoplasmic reticulum, 252
 voltage changes
 cable system, 73–74
 calcium ion release, 158–160
 tubular voltage detection, 164–167
 unmyelinated nerve, 75
 voltage-sensing modules (VSMs), 58
 sodium channels, 66–67
 voltage clamp experiments, 12, 46–47, 86
 end-plate potentials, 98
 ionic current, 137–138
 ionic current components, 49–52
 nerve membrane, 47–49
 voltage-gated ion channels, 55
 cDNA sequencing, 55, 57
 ion occupancy, 69–72
 ionic selectivity, 68–69
 sodium gating mechanism, 66–68
 structure of, 55–60
 Wallerian degeneration, 8
 Wheatstone bridge, 41
 white matter, 6
 work output, 186
Xenopus, 57, 103
 X-ray crystallography, 71
 X-ray diffraction, 4, 102, 116, 128, 130, 132
 Z-line, 123, 126, 132, 141